SCHEMBL2297887

SCHEMBL2297887

CCOC(=O)c1cc(-c2ccc(NC(=O)Nc3ccc(F)cc3)cc2)no1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.62
MEN1 O00255 6/20 0.62
KMT2A Q03164 6/20 0.62
CASP3 P42574 1/20 0.62
TRPV1 Q8NER1 1/20 0.62
SENP7 Q9BQF6 1/20 0.62
CSGALNACT1 Q8TDX6 11/20 0.59
ALDH1A1 P00352 2/20 0.56
SMN1; SMN2 Q16637 2/20 0.54
CYP1A2 P05177 1/20 0.51
CYP2C9 P11712 1/20 0.51
CYP2C19 P33261 1/20 0.51
NPC1 O15118 2/20 0.51
RAB9A P51151 2/20 0.51
HPGD P15428 1/20 0.51
NFKB1 P19838 1/20 0.51
NFKB2 Q00653 1/20 0.51
RELA Q04206 1/20 0.51
LMNA P02545 1/20 0.50
MAPK1 P28482 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2297570 0.91 CSGALNACT1 (0.56) MAPTMEN1KMT2ACASP3TRPV1
SCHEMBL2177301 0.91 MAPT (0.52) MAPTMEN1KMT2ACASP3TRPV1
SCHEMBL2293812 0.90 SMN1; SMN2 (0.57) MAPTMEN1KMT2ATRPV1CSGALNACT1
SCHEMBL2298617 0.87 RAB9A (0.57) MAPTMEN1KMT2ACSGALNACT1ALDH1A1
SCHEMBL3231890 0.85 SMN1; SMN2 (0.52) MAPTMEN1KMT2ATRPV1CSGALNACT1
SCHEMBL3227975 0.84 RAB9A (0.53) MAPTMEN1KMT2ACSGALNACT1ALDH1A1
SCHEMBL3237097 0.83 RAB9A (0.52) MAPTMEN1KMT2ACSGALNACT1ALDH1A1
SCHEMBL2295862 0.82 MEN1 (0.68) MAPTMEN1KMT2ACSGALNACT1ALDH1A1
SCHEMBL2299194 0.81 NPC1 (0.57) MAPTMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL2296373 0.80 CSGALNACT1 (0.51) MAPTMEN1KMT2ACSGALNACT1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2010023609-A1 OXAZOLE, OXADIAZOLE AND THIAZOLE DERIVATIVES AS DIACYLGLYCEROL ACYLTRANFERASE INHIBITORS PIRAMAL LIFE SCIENCES LIMITED (IN) 2010-03-04 WO claimed
US-8835428-B2 Diacylglycerol acyltransferase inhibitors Piramal Enterprises Limited (IN) 2014-09-16 US disclosed
US-20110196002-A1 DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS PIRAMAL LIFE SCIENCES LIMITED. 2011-08-11 US disclosed
WO-2010023609-A1 OXAZOLE, OXADIAZOLE AND THIAZOLE DERIVATIVES AS DIACYLGLYCEROL ACYLTRANFERASE INHIBITORS PIRAMAL LIFE SCIENCES LIMITED (IN) 2010-03-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110196002-A1 DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS DGAT1, DGAT2, DLAT MAPT 1278/4885MEN1 4530/4885KMT2A 1450/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.